Our research indicates that TILs, particularly CD8+, CD3+ and CD4+ TILs, are associated with improved prognosis in NSCLC, supporting the notion that these immune cells contribute to anti-tumor immunity. The gene discussed is CD8A; the disease is neoplasm.